On June 3, 2026, Aurobindo Pharma Limited reached a major strategic milestone with the inauguration of TheraNym, one of India’s largest dedicated biologics Contract Manufacturing Organisations (CMO). This bold foray into the biologics segment marks a defining moment for the company as it seeks to meet the rising global demand for biologic therapies.
The facility, operated by its subsidiary Theranym Biologics Private Limited, was inaugurated in the presence of key ministers from the Government of Telangana, underscoring the strong partnership between industry and state policy.
A State-of-the-Art Facility in Borapatla
Strategically located in Borapatla—approximately 45 minutes from Hyderabad’s Financial District—TheraNym is built to meet the highest international regulatory standards. The facility is equipped with world-class infrastructure designed to support a seamless global supply chain:
- 15 KL Bioreactors: Providing massive scale for biologic production.
- Advanced Processing: Includes high-end downstream suites and aseptic fill-finish capabilities.
- Quality Control: On-site laboratories ensure that every product meets rigorous global benchmarks.
Strategic Partnership with MSD
In a significant vote of confidence, the global pharmaceutical giant MSD has joined TheraNym as its anchor customer. This partnership is aimed at strengthening the global access to critical biologic medicines by adding meaningful capacity and capability to the MSD supply chain for both domestic and export markets.
According to Dr. Dave Maraldo, MSD Executive Vice President, this collaboration reflects a “shared commitment to strengthening global access to critical biologic medicines”.
Why Hyderabad? The Biotech Capital Advantage
TheraNym’s success is deeply rooted in the vibrant Hyderabad ecosystem, often referred to as India’s biotech capital. This ecosystem provides unique advantages that enable companies like Aurobindo to execute large-scale projects with confidence:
- Scientific Talent: Proximity to premier institutions like IITs, BITS, and the Centre for Cellular and Molecular Biology (CCMB) ensures a steady flow of world-class talent.
- Infrastructure & Logistics: A mature vendor network and proximity to an international airport facilitate rapid logistics for temperature-sensitive biologic products.
- Policy Support: Initiatives like the Telangana Life Sciences Policy and the National Biopharma Mission have created a collaborative culture between industry and government.
Charting the Next Phase of Growth
For Aurobindo Pharma, TheraNym represents more than just a new factory; it is a “core differentiator” in their journey toward becoming an integrated biologics player. Building on their previous biosimilar efforts with CuraTeQ, the company is now prioritizing the high-growth biologics CMO market.
As Dr. Satakarni Makkapati, CEO of Biologics at Aurobindo Pharma, noted, “TheraNym stands ready to help bring biologic therapies to patients worldwide, reliably and more affordably than before”.
With a global footprint spanning over 150 countries, Aurobindo Pharma is now well-positioned to capture a dominant share of the global biologics market, delivering both economic and public health dividends for the nation.
source: corporate announcement nseindia.com